Sector News

Boston Scientific elects Yoshiaki Fujimori to Board

July 13, 2016
Life sciences

Boston Scientific Corporation announced today the election of Yoshiaki Fujimori to its board of directors, effective immediately.

Yoshiaki Fujimori is an adviser to the LIXIL Group Corporation (“LIXIL”), for which he served as president and chief executive officer from 2011 to 2016. Prior to joining LIXIL, Mr. Fujimori spent 25 years with GE, including positions as senior vice president and chief executive officer (CEO) of a number of Asian and global business divisions, including Medical Systems, Plastics and Capital, and was a member of the Corporate Executive Council before serving as chairman, president and CEO of GE Japan for more than three years. Mr. Fujimori started his career at Japanese trading company Nissho Iwai Corporation (now Sojitz).

Mr. Fujimori serves as an external director of Tokyo Electric Power Company, a role he has held since June 2012. He is also an external director for Takeda Pharmaceutical Company Limited. He previously served as chairman of the Japan Construction Material & Housing Equipment Industries Federation. He received his bachelor’s degree in petroleum engineering from the University of Tokyo and his master’s degree from Carnegie Mellon Graduate School of Business, where he serves as a lifetime member of the Board of Trustees.

“Fujimori-san is an accomplished business leader and brings significant insights on how large companies plan, execute and compete globally to our Board,” said Mike Mahoney, chief executive officer and chairman of the board, Boston Scientific. “We are delighted to welcome him to the Board.”

Source: Boston Scientific

comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach